Alzheimer's disease biomarkers: Correspondence between human studies and animal models

Neurobiology of Disease

Volumn 56, Issue , 2013, Pages 116-130

  Sabbagh, Jonathan J ^a   Kinney, Jefferson W ^a   Cummings, Jeffrey L ^b  

^a UNIVERSITY OF NEVADA   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Animal models; Biomarkers; Review

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; PRESENILIN 1; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; BRAIN RADIOGRAPHY; CEREBROSPINAL FLUID; DISEASE MODEL; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; FUNCTIONAL NEUROIMAGING; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLATIONAL RESEARCH;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; ELECTROENCEPHALOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; POSITRON-EMISSION TOMOGRAPHY;

EID: 84878134300     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.04.010     Document Type: Review

References (281)

1. Abdi F., Quinn J.F., Jankovic J., McIntosh M., Leverenz J.B., Peskind E., Nixon R., Nutt J., Chung K., Zabetian C., Samii A., Lin M., Hattan S., Pan C., Wang Y., Jin J., Zhu D., Li G.J., Liu Y., Waichunas D., Montine T.J., Zhang J. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J. Alzheimers Dis. 2006, 9(3):293-348. ([Internet], Aug).
2. Alsop D.C., Detre J.A., Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann. Neurol. 2000, 47(1):93-100. ([Internet], Jan).
3. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement. 2012, 8(2):131-168. ([Internet], Mar).
4. Anderson J.J., Holtz G., Baskin P.P., Turner M., Rowe B., Wang B., Kounnas M.Z., Lamb B.T., Barten D., Felsenstein K., McDonald I., Srinivasan K., Munoz B., Wagner S.L. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 2005, 69(4):689-698. ([Internet], Feb 15).
5. Arnaiz E., Jelic V., Almkvist O., Wahlund L.O., Winblad B., Valind S., Nordberg A. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001, 12(4):851-855. ([Internet], Mar 26).
6. Babiloni C., Ferri R., Moretti D.V., Strambi A., Binetti G., Dal Forno G., Ferreri F., Lanuzza B., Bonato C., Nobili F., Rodriguez G., Salinari S., Passero S., Rocchi R., Stam C.J., Rossini P.M. Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. Eur. J. Neurosci. 2004, 19(9):2583-2590. ([Internet], May).
7. Babiloni C., Vecchio F., Lizio R., Ferri R., Rodriguez G., Marzano N., Frisoni G.B., Rossini P.M. Resting state cortical rhythms in mild cognitive impairment and Alzheimer's disease: electroencephalographic evidence. J. Alzheimers Dis. 2011, 26(Suppl. 3):201-214. (Internet).
8. Barten D.M., Cadelina G.W., Hoque N., DeCarr L.B., Guss V.L., Yang L., Sankaranarayanan S., Wes P.D., Flynn M.E., Meredith J.E., Ahlijanian M.K., Albright C.F. Tau transgenic mice as models for cerebrospinal fluid tau biomarkers. J. Alzheimers Dis. 2011, 24(Suppl. 2):127-141. (Internet).
9. 18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study. Lancet Neurol. 2011, 10(5):424-435. ([Internet], May).
10. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 2006, 12(7):856-861. ([Internet], Jul).
11. Bateman R.J., Siemers E.R., Mawuenyega K.G., Wen G., Browning K.R., Sigurdson W.C., Yarasheski K.E., Friedrich S.W., Demattos R.B., May P.C., Paul S.M., Holtzman D.M. A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann. Neurol. 2009, 66(1):48-54. ([Internet], Jul).
12. Beckmann N., Gerard C., Abramowski D., Cannet C., Staufenbiel M. Noninvasive magnetic resonance imaging detection of cerebral amyloid angiopathy-related microvascular alterations using superparamagnetic iron oxide particles in APP transgenic mouse models of Alzheimer's disease: application to passive abeta immunotherapy. J. Neurosci. 2011, 31(3):1023-1031. ([Internet], Jan 19).
13. Bentley P., Driver J., Dolan R.J. Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health. Brain 2008, 131(Pt 2):409-424. ([Internet], Feb).
14. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006, 21(1):9-15. (Internet).
15. Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 2004, 1(2):213-225. ([Internet], Apr).
16. Blennow K., Zetterberg H., Minthon L., Lannfelt L., Strid S., Annas P., Basun H., Andreasen N. Longitudinal stability of CSF biomarkers in Alzheimer's disease. Neurosci. Lett. 2007, 419(1):18-22. ([Internet], May 23).
17. Bokde A.L., Karmann M., Teipel S.J., Born C., Lieb M., Reiser M.F., Moller H.J., Hampel H. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild alzheimer disease: a functional magnetic resonance imaging study. J. Clin. Psychopharmacol. 2009, 29(2):147-156. ([Internet], Apr).
18. Borthakur A., Gur T., Wheaton A.J., Corbo M., Trojanowski J.Q., Lee V.M., Reddy R. In vivo measurement of plaque burden in a mouse model of Alzheimer's disease. J. Magn. Reson. Imaging 2006, 24(5):1011-1017. ([Internet], Nov).
19. Bozzali M., Falini A., Franceschi M., Cercignani M., Zuffi M., Scotti G., Comi G., Filippi M. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging. J. Neurol. Neurosurg. Psychiatry 2002, 72(6):742-746. ([Internet], Jun).
20. Buchhave P., Minthon L., Zetterberg H., Wallin A.K., Blennow K., Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 2012, 69(1):98-106. ([Internet], Jan).
21. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttila T., Schapiro M.B., Rapoport S.I., Moller H.J., Davies P., Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 2002, 59(8):1267-1272. ([Internet], Aug).
22. Buerger K., Teipel S.J., Zinkowski R., Blennow K., Arai H., Engel R., Hofmann-Kiefer K., McCulloch C., Ptok U., Heun R., Andreasen N., DeBernardis J., Kerkman D., Moeller H., Davies P., Hampel H. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 2002, 59(4):627-629. ([Internet], Aug 27).
23. Cagnin A., Brooks D.J., Kennedy A.M., Gunn R.N., Myers R., Turkheimer F.E., Jones T., Banati R.B. In-vivo measurement of activated microglia in dementia. Lancet 2001, 358(9280):461-467. ([Internet], Aug 11).
24. 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur. J. Nucl. Med. Mol. Imaging 2012, 39(4):621-631. ([Internet], Apr).
25. Cao C., Arendash G.W., Dickson A., Mamcarz M.B., Lin X., Ethell D.W. Abeta-specific Th2 cells provide cognitive and pathological benefits to Alzheimer's mice without infiltrating the CNS. Neurobiol. Dis. 2009, 34(1):63-70. ([Internet], Apr).
26. Carlson N.E., Moore M.M., Dame A., Howieson D., Silbert L.C., Quinn J.F., Kaye J.A. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology 2008, 70(11):828-833. ([Internet], Mar 11).
27. Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., Hochstrasser D.F., Sanchez J.C. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003, 3(8):1486-1494. ([Internet], Aug).
28. Celone K.A., Calhoun V.D., Dickerson B.C., Atri A., Chua E.F., Miller S.L., DePeau K., Rentz D.M., Selkoe D.J., Blacker D., Albert M.S., Sperling R.A. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J. Neurosci. 2006, 26(40):10222-10231. ([Internet], Oct 4).
29. Ceravolo R., Volterrani D., Gambaccini G., Rossi C., Logi C., Manca G., Berti C., Mariani G., Murri L., Bonuccelli U. Dopaminergic degeneration and perfusional impairment in lewy body dementia and Alzheimer's disease. Neurol. Sci. 2003, 24(3):162-163. ([Internet], Oct).
30. Chao L.L., Schuff N., Kramer J.H., Du A.T., Capizzano A.A., O'Neill J., Wolkowitz O.M., Jagust W.J., Chui H.C., Miller B.L., Yaffe K., Weiner M.W. Reduced medial temporal lobe N-acetylaspartate in cognitively impaired but nondemented patients. Neurology 2005, 64(2):282-289. ([Internet], Jan 25).
31. Chao L.L., Buckley S.T., Kornak J., Schuff N., Madison C., Yaffe K., Miller B.L., Kramer J.H., Weiner M.W. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis. Assoc. Disord. 2010, 24(1):19-27. ([Internet], Jan-Mar).
32. Chen S.Q., Wang P.J., Ten G.J., Zhan W., Li M.H., Zang F.C. Role of myo-inositol by magnetic resonance spectroscopy in early diagnosis of Alzheimer's disease in APP/PS1 transgenic mice. Dement. Geriatr. Cogn. Disord. 2009, 28(6):558-566. (Internet).
33. Chen K., Langbaum J.B., Fleisher A.S., Ayutyanont N., Reschke C., Lee W., Liu X., Bandy D., Alexander G.E., Thompson P.M., Foster N.L., Harvey D.J., de Leon M.J., Koeppe R.A., Jagust W.J., Weiner M.W., Reiman E.M., Alzheimer's Disease Neuroimaging Initiative Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's disease neuroimaging initiative. Neuroimage 2010, 51(2):654-664. ([Internet], Jun).
34. Chen Y., Wolk D.A., Reddin J.S., Korczykowski M., Martinez P.M., Musiek E.S., Newberg A.B., Julin P., Arnold S.E., Greenberg J.H., Detre J.A. Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011, 77(22):1977-1985. ([Internet], Nov 29).
35. 18F-AV-45: A PET agent for abeta plaques in the brain. J. Nucl. Med. 2009, 50(11):1887-1894. ([Internet], Nov).
36. Choi J.K., Jenkins B.G., Carreras I., Kaymakcalan S., Cormier K., Kowall N.W., Dedeoglu A. Anti-inflammatory treatment in AD mice protects against neuronal pathology. Exp. Neurol. 2010, 223(2):377-384. ([Internet], Jun).
37. Choi S.R., Schneider J.A., Bennett D.A., Beach T.G., Bedell B.J., Zehntner S.P., Krautkramer M.J., Kung H.F., Skovronsky D.M., Hefti F., Clark C.M. Correlation of amyloid PET ligand florbetapir F 18 binding with abeta aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis. Assoc. Disord. 2012, 26(1):8-16. ([Internet], Jan).
38. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., Pontecorvo M.J., Hefti F., Carpenter A.P., Flitter M.L., Krautkramer M.J., Kung H.F., Coleman R.E., Doraiswamy P.M., Fleisher A.S., Sabbagh M.N., Sadowsky C.H., Reiman E.P., Zehntner S.P., Skovronsky D.M., AV45-A07 Study Group Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305(3):275-283. ([Internet], Jan 19).
39. 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int. Psychogeriatr. 2008, 20(6):1124-1140. ([Internet], Dec).
40. 123I-5IA-85380 single photon emission computed tomography as a predictor of cognitive progression in Alzheimer's disease and dementia with Lewy bodies. Am. J. Geriatr. Psychiatry 2010, 18(1):86-90. ([Internet], Jan).
41. Colloby S.J., McParland S., O'Brien J.T., Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012, 135(Pt 9):2798-2808. ([Internet], Sep).
42. Cook J.J., Wildsmith K.R., Gilberto D.B., Holahan M.A., Kinney G.G., Mathers P.D., Michener M.S., Price E.A., Shearman M.S., Simon A.J., Wang J.X., Wu G., Yarasheski K.E., Bateman R.J. Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound. J. Neurosci. 2010, 30(19):6743-6750. ([Internet], May 12).
43. Corsi M.M., Licastro F., Porcellini E., Dogliotti G., Galliera E., Lamont J.L., Innocenzi P.J., Fitzgerald S.P. Reduced plasma levels of P-selectin and L-selectin in a pilot study from alzheimer disease: relationship with neuro-degeneration. Biogerontology 2011, 12(5):451-454. ([Internet], Oct).
44. Craig-Schapiro R., Kuhn M., Xiong C., Pickering E.H., Liu J., Misko T.P., Perrin R.J., Bales K.R., Soares H., Fagan A.M., Holtzman D.M. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011, 6(4):e18850. ([Internet], Apr 19).
45. Cui M., Ono M., Kimura H., Kawashima H., Liu B.L., Saji H. Radioiodinated benzimidazole derivatives as single photon emission computed tomography probes for imaging of beta-amyloid plaques in Alzheimer's disease. Nucl. Med. Biol. 2011, 38(3):313-320. ([Internet], Apr).
46. Cummings J.L. Biomarkers in Alzheimer's disease drug development. Alzheimers Dement. 2011, 7(3):e13-e44. ([Internet], May).
47. Cummings J.L. Alzheimer's disease clinical trials: changing the paradigm. Curr. Psychiatry Rep. 2011, 13(6):437-442. ([Internet], Dec).
48. Cummings B.J., Head E., Afagh A.J., Milgram N.W., Cotman C.W. Beta-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiol. Learn. Mem. 1996, 66(1):11-23. ([Internet], Jul).
49. Cummings J.L., Henchcliffe C., Schaier S., Simuni T., Waxman A., Kemp P. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 2011, 134(Pt 11):3146-3166. ([Internet], Nov).
50. Dai W., Lopez O.L., Carmichael O.T., Becker J.T., Kuller L.H., Gach H.M. Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009, 250(3):856-866. ([Internet], Mar).
51. Dashjamts T., Yoshiura T., Hiwatashi A., Yamashita K., Monji A., Ohyagi Y., Kamano H., Kawashima T., Kira J., Honda H. Simultaneous arterial spin labeling cerebral blood flow and morphological assessments for detection of Alzheimer's disease. Acad. Radiol. 2011, 18(12):1492-1499. ([Internet], Dec).
52. Davidsson P., Westman-Brinkmalm A., Nilsson C.L., Lindbjer M., Paulson L., Andreasen N., Sjogren M., Blennow K. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002, 13(5):611-615. ([Internet], Apr 16).
53. de Haan W., Pijnenburg Y.A., Strijers R.L., van der Made Y., van der Flier W.M., Scheltens P., Stam C.J. Functional neural network analysis in frontotemporal dementia and Alzheimer's disease using EEG and graph theory. BMC Neurosci. 2009, 10:101. ([Internet], Aug 21).
54. de Leon M.J., Mosconi L., Li J., De Santi S., Yao Y., Tsui W.H., Pirraglia E., Rich K., Javier E., Brys M., Glodzik L., Switalski R., Saint Louis L.A., Pratico D. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J. Neurol. 2007, 254(12):1666-1675. ([Internet], Dec).
55. Decourt B., Sabbagh M.N. BACE1 as a potential biomarker for Alzheimer's disease. J. Alzheimers Dis. 2011, 24(Suppl. 2):53-59. (Internet).
56. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res. 2004, 1012(1-2):60-65. ([Internet], Jun 25).
57. DeMattos R.B., Bales K.R., Parsadanian M., O'Dell M.A., Foss E.M., Paul S.M., Holtzman D.M. Plaque-associated disruption of CSF and plasma amyloid-beta (abeta) equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 2002, 81(2):229-236. ([Internet], Apr).
58. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26(22):6011-6018. ([Internet], May 31).
59. Dhenain M., Privat N., Duyckaerts C., Jacobs R.E. Senile plaques do not induce susceptibility effects in T2*-weighted MR microscopic images. NMR Biomed. 2002, 15(3):197-203. ([Internet], May).
60. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., Bertram L., Mullin K., Tanzi R.E., Blacker D., Albert M.S., Sperling R.A. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005, 65(3):404-411. ([Internet], Aug 9).
61. Dierks T., Jelic V., Pascual-Marqui R.D., Wahlund L., Julin P., Linden D.E., Maurer K., Winblad B., Nordberg A. Spatial pattern of cerebral glucose metabolism (PET) correlates with localization of intracerebral EEG-generators in Alzheimer's disease. Clin. Neurophysiol. 2000, 111(10):1817-1824. ([Internet], Oct).
62. Drzezga A., Riemenschneider M., Strassner B., Grimmer T., Peller M., Knoll A., Wagenpfeil S., Minoshima S., Schwaiger M., Kurz A. Cerebral glucose metabolism in patients with AD and different APOE genotypes. Neurology 2005, 64(1):102-107. ([Internet], Jan 11).
63. Dubois A., Herard A.S., Delatour B., Hantraye P., Bonvento G., Dhenain M., Delzescaux T. Detection by voxel-wise statistical analysis of significant changes in regional cerebral glucose uptake in an APP/PS1 transgenic mouse model of Alzheimer's disease. Neuroimage 2010, 51(2):586-598. ([Internet], Jun).
64. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118(1):5-36. ([Internet], Jul).
65. 18F]FDG PET study. Neurology 2007, 68(7):501-508. ([Internet], Feb 13).
66. 11C]PIB-PET study. Neurobiol. Dis. 2008, 32(3):412-419. ([Internet], Dec).
67. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Reduction of abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for abeta production inhibitors. Curr. Pharm. Des. 2006, 12(6):671-676. (Internet).
68. Englund H., Sehlin D., Johansson A.S., Nilsson L.N., Gellerfors P., Paulie S., Lannfelt L., Pettersson F.E. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J. Neurochem. 2007, 103(1):334-345. ([Internet], Oct).
69. Englund H., Degerman Gunnarsson M., Brundin R.M., Hedlund M., Kilander L., Lannfelt L., Pettersson F.E. Oligomerization partially explains the lowering of Abeta42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis 2009, 6(4):139-147. (Internet).
70. Ewers M., Zhong Z., Burger K., Wallin A., Blennow K., Teipel S.J., Shen Y., Hampel H. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 2008, 131(Pt 5):1252-1258. ([Internet], May).
71. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., DeKosky S.T., Morris J.C., Holtzman D.M. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59(3):512-519. ([Internet], Mar).
72. Fagan A.M., Roe C.M., Xiong C., Mintun M.A., Morris J.C., Holtzman D.M. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch. Neurol. 2007, 64(3):343-349. ([Internet], Mar).
73. Faure A., Verret L., Bozon B., El Tannir El Tayara N., Ly M., Kober F., Dhenain M., Rampon C., Delatour B. Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-ki mouse model of Alzheimer's disease. Neurobiol. Aging 2011, 32(3):407-418. ([Internet], Mar).
74. Fellgiebel A., Wille P., Muller M.J., Winterer G., Scheurich A., Vucurevic G., Schmidt L.G., Stoeter P. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement. Geriatr. Cogn. Disord. 2004, 18(1):101-108. (Internet).
75. Finehout E.J., Franck Z., Choe L.H., Relkin N., Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 2007, 61(2):120-129. ([Internet], Feb).
76. Fleisher A.S., Sherzai A., Taylor C., Langbaum J.B., Chen K., Buxton R.B. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. Neuroimage 2009, 47(4):1678-1690. ([Internet], Oct 1).
77. Fleisher A.S., Chen K., Liu X., Roontiva A., Thiyyagura P., Ayutyanont N., Joshi A.D., Clark C.M., Mintun M.A., Pontecorvo M.J., Doraiswamy P.M., Johnson K.A., Skovronsky D.M., Reiman E.M. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to alzheimer disease. Arch. Neurol. 2011, 68(11):1404-1411. ([Internet], Nov).
78. 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011, 134(Pt 4):1089-1100. ([Internet], Apr).
79. Frederick B.D., Lyoo I.K., Satlin A., Ahn K.H., Kim M.J., Yurgelun-Todd D.A., Cohen B.M., Renshaw P.F. In vivo proton magnetic resonance spectroscopy of the temporal lobe in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28(8):1313-1322. ([Internet], Dec).
80. Fukumoto H., Tokuda T., Kasai T., Ishigami N., Hidaka H., Kondo M., Allsop D., Nakagawa M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J. 2010, 24(8):2716-2726. ([Internet], Aug).
81. Galimberti D., Schoonenboom N., Scheltens P., Fenoglio C., Venturelli E., Pijnenburg Y.A., Bresolin N., Scarpini E. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006, 66(1):146-147. ([Internet], Jan 10).
82. Galimberti D., Venturelli E., Fenoglio C., Guidi I., Villa C., Bergamaschini L., Cortini F., Scalabrini D., Baron P., Vergani C., Bresolin N., Scarpini E. Intrathecal levels of IL-6, IL-11 and LIF in Alzheimer's disease and frontotemporal lobar degeneration. J. Neurol. 2008, 255(4):539-544. ([Internet], Apr).
83. Galvin J.E., Price J.L., Yan Z., Morris J.C., Sheline Y.I. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 2011, 76(21):1797-1803. ([Internet], May 24).
84. Georganopoulou D.G., Chang L., Nam J.M., Thaxton C.S., Mufson E.J., Klein W.L., Mirkin C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(7):2273-2276. ([Internet], Feb 15).
85. German D.C., Gurnani P., Nandi A., Garner H.R., Fisher W., Diaz-Arrastia R., O'Suilleabhain P., Rosenblatt K.P. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed. Pharmacother. 2007, 61(7):383-389. ([Internet], Aug).
86. Goekoop R., Rombouts S.A., Jonker C., Hibbel A., Knol D.L., Truyen L., Barkhof F., Scheltens P. Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. Neuroimage 2004, 23(4):1450-1459. ([Internet], Dec).
87. Golby A., Silverberg G., Race E., Gabrieli S., O'Shea J., Knierim K., Stebbins G., Gabrieli J. Memory encoding in Alzheimer's disease: an fMRI study of explicit and implicit memory. Brain 2005, 128(Pt 4):773-787. ([Internet], Apr).
88. Gonzales A., Decourt B., Walker A., Condjella R., Nural H., Sabbagh M.N. Development of a specific ELISA to measure BACE1 levels in human tissues. J. Neurosci. Methods 2011, 202(1):70-76. ([Internet], Oct 30).
89. Gonzalez-Martinez A., Rosado B., Pesini P., Suarez M.L., Santamarina G., Garcia-Belenguer S., Villegas A., Monleon I., Sarasa M. Plasma beta-amyloid peptides in canine aging and cognitive dysfunction as a model of Alzheimer's disease. Exp. Gerontol. 2011, 46(7):590-596. ([Internet], Jul).
90. Goveas J.S., Xie C., Ward B.D., Wu Z., Li W., Franczak M., Jones J.L., Antuono P.G., Li S.J. Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer's disease patients treated with donepezil assessed by resting-state fMRI. J. Magn. Reson. Imaging 2011, 34(4):764-773. ([Internet], Oct).
91. Grady C.L., McIntosh A.R., Beig S., Keightley M.L., Burian H., Black S.E. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J. Neurosci. 2003, 23(3):986-993. ([Internet], Feb 1).
92. Greicius M.D., Srivastava G., Reiss A.L., Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(13):4637-4642. ([Internet], Mar 30).
93. Grossman M., Farmer J., Leight S., Work M., Moore P., Van Deerlin V., Pratico D., Clark C.M., Coslett H.B., Chatterjee A., Gee J., Trojanowski J.Q., Lee V.M. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 2005, 57(5):721-729. ([Internet], May).
94. Hampel H., Schoen D., Schwarz M.J., Kotter H.U., Schneider C., Sunderland T., Dukoff R., Levy J., Padberg F., Stubner S., Buch K., Muller N., Moller H.J. Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease. Neurosci. Lett. 1997, 228(3):143-146. ([Internet], Jun 13).
95. Hampel H., Teipel S.J., Fuchsberger T., Andreasen N., Wiltfang J., Otto M., Shen Y., Dodel R., Du Y., Farlow M., Moller H.J., Blennow K., Buerger K. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol. Psychiatry 2004, 9(7):705-710. ([Internet], Jul).
96. Hampel H., Frank R., Broich K., Teipel S.J., Katz R.G., Hardy J., Herholz K., Bokde A.L., Jessen F., Hoessler Y.C., Sanhai W.R., Zetterberg H., Woodcock J., Blennow K. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat. Rev. Drug Discov. 2010, 9(7):560-574. ([Internet], Jul).
97. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 2006, 5(3):228-234. ([Internet], Mar).
98. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 2007, 23(5):316-320. (Internet).
99. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., Blennow K. Evaluation of plasma abeta(40) and abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging 2010, 31(3):357-367. ([Internet], Mar).
100. Hawkins J., Harrison D.C., Ahmed S., Davis R.P., Chapman T., Marshall I., Smith B., Mead T.L., Medhurst A., Giblin G.M., Hall A., Gonzalez M.I., Richardson J., Hussain I. Dynamics of Abeta42 reduction in plasma, CSF and brain of rats treated with the gamma-secretase modulator, GSM-10h. Neurodegener Dis 2011, 8(6):455-464. (Internet).
101. Head E., Pop V., Sarsoza F., Kayed R., Beckett T.L., Studzinski C.M., Tomic J.L., Glabe C.G., Murphy M.P. Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J. Alzheimers Dis. 2010, 20(2):637-646. (Internet).
102. Heo J.H., Lee S.R., Lee S.T., Lee K.M., Oh J.H., Jang D.P., Chang K.T., Cho Z.H. Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J. Alzheimers Dis. 2011, 25(3):517-523. (Internet).
103. Higuchi M. Visualization of brain amyloid and microglial activation in mouse models of Alzheimer's disease. Curr. Alzheimer Res. 2009, 6(2):137-143. ([Internet], Apr).
104. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido T.C. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat. Neurosci. 2005, 8(4):527-533. ([Internet], Apr).
105. Holsinger R.M., McLean C.A., Collins S.J., Masters C.L., Evin G. Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects. Ann. Neurol. 2004, 55(6):898-899. ([Internet], Jun).
106. Holtzman D.M. CSF biomarkers for Alzheimer's disease: current utility and potential future use. Neurobiol. Aging 2011, 32(Suppl. 1):S4-S9. ([Internet], Dec).
107. Hook G., Hook V., Kindy M. The cysteine protease inhibitor, E64d, reduces brain amyloid-beta and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, beta-secretase activity. J. Alzheimers Dis. 2011, 26(2):387-408. (Internet).
108. Hu Z.H., Wang X.C., Li L.Y., Liu M.L., Liu R., Ling Z., Tian Q., Tang X.W., Wu Y.G., Wang J.Z. Correlation of behavior changes and BOLD signal in alzheimer-like rat model. Acta Biochim. Biophys. Sin. (Shanghai) 2004, 36(12):803-810. ([Internet], Dec).
109. Huang C., Wahlund L., Dierks T., Julin P., Winblad B., Jelic V. Discrimination of Alzheimer's disease and mild cognitive impairment by equivalent EEG sources: a cross-sectional and longitudinal study. Clin. Neurophysiol. 2000, 111(11):1961-1967. ([Internet], Nov).
110. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 2006, 129(Pt 11):3042-3050. ([Internet], Nov).
111. Irizarry M.C., Yao Y., Hyman B.T., Growdon J.H., Pratico D. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener Dis 2007, 4(6):403-405. (Internet).
112. Itoh N., Arai H., Urakami K., Ishiguro K., Ohno H., Hampel H., Buerger K., Wiltfang J., Otto M., Kretzschmar H., Moeller H.J., Imagawa M., Kohno H., Nakashima K., Kuzuhara S., Sasaki H., Imahori K. Large-scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease. Ann. Neurol. 2001, 50(2):150-156. ([Internet], Aug).
113. Jack C.R., Petersen R.C., Xu Y.C., Waring S.C., O'Brien P.C., Tangalos E.G., Smith G.E., Ivnik R.J., Kokmen E. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997, 49(3):786-794. ([Internet], Sep).
114. Jack C.R., Petersen R.C., Xu Y.C., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Waring S.C., Tangalos E.G., Kokmen E. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999, 52(7):1397-1403. ([Internet], Apr 22).
115. Jack C.R., Petersen R.C., Xu Y., O'Brien P.C., Smith G.E., Ivnik R.J., Boeve B.F., Tangalos E.G., Kokmen E. Rates of hippocampal atrophy correlate with change in clinical status in aging and AD. Neurology 2000, 55(4):484-489. ([Internet], Aug 22).
116. Jack C.R., Garwood M., Wengenack T.M., Borowski B., Curran G.L., Lin J., Adriany G., Grohn O.H., Grimm R., Poduslo J.F. In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magn. Reson. Med. 2004, 52(6):1263-1271. ([Internet], Dec).
117. Jack C.R., Wengenack T.M., Reyes D.A., Garwood M., Curran G.L., Borowski B.J., Lin J., Preboske G.M., Holasek S.S., Adriany G., Poduslo J.F. In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. J. Neurosci. 2005, 25(43):10041-10048. ([Internet], Oct 26).
118. Jagust W.J., Landau S.M., Shaw L.M., Trojanowski J.Q., Koeppe R.A., Reiman E.M., Foster N.L., Petersen R.C., Weiner M.W., Price J.C., Mathis C.A., Alzheimer's Disease Neuroimaging Initiative Relationships between biomarkers in aging and dementia. Neurology 2009, 73(15):1193-1199. ([Internet], Oct 13).
119. Jelic V., Johansson S.E., Almkvist O., Shigeta M., Julin P., Nordberg A., Winblad B., Wahlund L.O. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol. Aging 2000, 21(4):533-540. ([Internet], Jul-Aug).
120. Jessen F., Block W., Traber F., Keller E., Flacke S., Lamerichs R., Schild H.H., Heun R. Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology 2001, 57(5):930-932. ([Internet], Sep 11).
121. 1H-MRS study of the medial temporal lobe in AD and MCI. Neurology 2009, 72(20):1735-1740. ([Internet], May 19).
122. Jia J.P., Meng R., Sun Y.X., Sun W.J., Ji X.M., Jia L.F. Cerebrospinal fluid tau, Abeta1-42 and inflammatory cytokines in patients with Alzheimer's disease and vascular dementia. Neurosci. Lett. 2005, 383(1-2):12-16. ([Internet], Jul 22-29).
123. Johnson N.A., Jahng G.H., Weiner M.W., Miller B.L., Chui H.C., Jagust W.J., Gorno-Tempini M.L., Schuff N. Pattern of cerebral hypoperfusion in alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience. Radiology 2005, 234(3):851-859. ([Internet], Mar).
124. Jyoti A., Plano A., Riedel G., Platt B. EEG, activity, and sleep architecture in a transgenic AbetaPPswe/PSEN1A246E Alzheimer's disease mouse. J. Alzheimers Dis. 2010, 22(3):873-887. (Internet).
125. Kandimalla K.K., Wengenack T.M., Curran G.L., Gilles E.J., Poduslo J.F. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. J. Pharmacol. Exp. Ther. 2007, 322(2):541-549. ([Internet], Aug).
126. 1H MRS study. Neurology 2000, 55(2):210-217. ([Internet], Jul 25).
127. Kato T., Knopman D., Liu H. Dissociation of regional activation in mild AD during visual encoding: A functional MRI study. Neurology 2001, 57(5):812-816. ([Internet], Sep 11).
128. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2001, 21(2):372-381. ([Internet], Jan 15).
129. Killiany R.J., Gomez-Isla T., Moss M., Kikinis R., Sandor T., Jolesz F., Tanzi R., Jones K., Hyman B.T., Albert M.S. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease. Ann. Neurol. 2000, 47(4):430-439. ([Internet], Apr).
130. Kim H.D., Tahara K., Maxwell J.A., Lalonde R., Fukuiwa T., Fujihashi K., Van Kampen K.R., Kong F.K., Tang D.C., Fukuchi K. Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a mo/hu APPswe PS1dE9 mouse model of Alzheimer's disease. J. Gene Med. 2007, 9(2):88-98. ([Internet], Feb).
131. Kim J., Choi I.Y., Michaelis M.L., Lee P. Quantitative in vivo measurement of early axonal transport deficits in a triple transgenic mouse model of Alzheimer's disease using manganese-enhanced MRI. Neuroimage 2011, 56(3):1286-1292. ([Internet], Jun 1).
132. Kim Y.H., Lee E.K., Park S.A., Kim N.H., Kim C.W. Proteomic analysis of plasma from a tau transgenic mouse. Int. J. Dev. Neurosci. 2012, 30(4):277-283. ([Internet], Jun).
133. Kircher T.T., Erb M., Grodd W., Leube D.T. Cortical activation during cholinesterase-inhibitor treatment in Alzheimer disease: preliminary findings from a pharmaco-fMRI study. Am. J. Geriatr. Psychiatry 2005, 13(11):1006-1013. ([Internet], Nov).
134. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., Bergstrom M., Savitcheva I., Huang G.F., Estrada S., Ausen B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., Langstrom B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 2004, 55(3):306-319. ([Internet], Mar).
135. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci. 2005, 25(46):10598-10606. ([Internet], Nov 16).
136. Koenig T., Prichep L., Dierks T., Hubl D., Wahlund L.O., John E.R., Jelic V. Decreased EEG synchronization in Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging 2005, 26(2):165-171. ([Internet], Feb).
137. Koffie R.M., Farrar C.T., Saidi L.J., William C.M., Hyman B.T., Spires-Jones T.L. Nanoparticles enhance brain delivery of blood-brain barrier-impermeable probes for in vivo optical and magnetic resonance imaging. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(46):18837-18842. ([Internet], Nov 15).
138. Kohnken R., Buerger K., Zinkowski R., Miller C., Kerkman D., DeBernardis J., Shen J., Moller H.J., Davies P., Hampel H. Detection of tau phosphorylated at threonine 231 in cerebrospinal fluid of Alzheimer's disease patients. Neurosci. Lett. 2000, 287(3):187-190. ([Internet], Jun 30).
139. Kozuki M., Kurata T., Miyazaki K., Morimoto N., Ohta Y., Ikeda Y., Abe K. Atorvastatin and pitavastatin protect cerebellar purkinje cells in AD model mice and preserve the cytokines MCP-1 and TNF-alpha. Brain Res. 2011, 1388:32-38. ([Internet], May 4).
140. Kulkarni P.V., Roney C.A., Antich P.P., Bonte F.J., Raghu A.V., Aminabhavi T.M. Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer's disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010, 2(1):35-47. ([Internet], Jan-Feb).
141. 18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol. 2009, 11(4):236-240. ([Internet], Jul-Aug).
142. Landau S.M., Harvey D., Madison C.M., Koeppe R.A., Reiman E.M., Foster N.L., Weiner M.W., Jagust W.J., Alzheimer's Disease Neuroimaging Initiative Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol. Aging 2011, 32(7):1207-1218. ([Internet], Jul).
143. Lang S. The role of peripheral benzodiazepine receptors (PBRs) in CNS pathophysiology. Curr. Med. Chem. 2002, 9(15):1411-1415. ([Internet], Aug).
144. Langbaum J.B., Chen K., Lee W., Reschke C., Bandy D., Fleisher A.S., Alexander G.E., Foster N.L., Weiner M.W., Koeppe R.A., Jagust W.J., Reiman E.M., Alzheimer's Disease Neuroimaging Initiative Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's disease neuroimaging initiative (ADNI). Neuroimage 2009, 45(4):1107-1116. ([Internet], May 1).
145. Lau J.C., Lerch J.P., Sled J.G., Henkelman R.M., Evans A.C., Bedell B.J. Longitudinal neuroanatomical changes determined by deformation-based morphometry in a mouse model of Alzheimer's disease. Neuroimage 2008, 42(1):19-27. ([Internet], Aug 1).
146. Lautner R., Mattsson N., Scholl M., Augutis K., Blennow K., Olsson B., Zetterberg H. Biomarkers for microglial activation in Alzheimer's disease. Int. J. Alzheimers Dis. 2011, 2011:939426. (Internet).
147. Lee S.P., Falangola M.F., Nixon R.A., Duff K., Helpern J.A. Visualization of beta-amyloid plaques in a transgenic mouse model of Alzheimer's disease using MR microscopy without contrast reagents. Magn. Reson. Med. 2004, 52(3):538-544. ([Internet], Sep).
148. 1H-MRS neurochemical profiling in neurological and psychiatric disorders. Bioanalysis 2012, 4(14):1787-1804. ([Internet], Jul).
149. Lemere C.A., Beierschmitt A., Iglesias M., Spooner E.T., Bloom J.K., Leverone J.F., Zheng J.B., Seabrook T.J., Louard D., Li D., Selkoe D.J., Palmour R.M., Ervin F.R. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the caribbean vervet. Am. J. Pathol. 2004, 165(1):283-297. ([Internet], Jul).
150. Lewczuk P., Esselmann H., Otto M., Maler J.M., Henkel A.W., Henkel M.K., Eikenberg O., Antz C., Krause W.R., Reulbach U., Kornhuber J., Wiltfang J. Neurochemical diagnosis of Alzheimer's dementia by CSF Abeta42, Abeta42/Abeta40 ratio and total tau. Neurobiol. Aging 2004, 25(3):273-281. ([Internet], Mar).
151. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., Grimaldi L.M. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 2000, 103(1):97-102. ([Internet], Feb 1).
152. 18F]AV-45, a novel amyloid imaging agent-a pilot study. Nucl. Med. Biol. 2010, 37(4):497-508. ([Internet], May).
153. Lopez M.F., Mikulskis A., Kuzdzal S., Bennett D.A., Kelly J., Golenko E., DiCesare J., Denoyer E., Patton W.F., Ediger R., Sapp L., Ziegert T., Lynch C., Kramer S., Whiteley G.R., Wall M.R., Mannion D.P., Della Cioppa G., Rakitan J.S., Wolfe G.M. High-resolution serum proteomic profiling of alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 2005, 51(10):1946-1954. ([Internet], Oct).
154. Lord A., Englund H., Soderberg L., Tucker S., Clausen F., Hillered L., Gordon M., Morgan D., Lannfelt L., Pettersson F.E., Nilsson L.N. Amyloid-beta protofibril levels correlate with spatial learning in arctic Alzheimer's disease transgenic mice. FEBS J. 2009, 276(4):995-1006. ([Internet], Feb).
155. Luo F., Seifert T.R., Edalji R., Loebbert R.W., Hradil V.P., Harlan J., Schmidt M., Nimmrich V., Cox B.F., Fox G.B. Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 2008, 155(1):263-269. ([Internet], Jul 31).
156. Luo F., Rustay N.R., Ebert U., Hradil V.P., Cole T.B., Llano D.A., Mudd S.R., Zhang Y., Fox G.B., Day M. Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: limitations as a translatable model of Alzheimer's disease. Neurobiol. Aging 2012, 33(5):933-944. ([Internet], May).
157. Machulda M.M., Ward H.A., Borowski B., Gunter J.L., Cha R.H., O'Brien P.C., Petersen R.C., Boeve B.F., Knopman D., Tang-Wai D.F., Ivnik R.J., Smith G.E., Tangalos E.G., Jack C.R. Comparison of memory fMRI response among normal, MCI, and Alzheimer's patients. Neurology 2003, 61(4):500-506. ([Internet], Aug 26).
158. Maeda J., Ji B., Irie T., Tomiyama T., Maruyama M., Okauchi T., Staufenbiel M., Iwata N., Ono M., Saido T.C., Suzuki K., Mori H., Higuchi M., Suhara T. Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 2007, 27(41):10957-10968. ([Internet], Oct 10).
159. Maeda J., Zhang M.R., Okauchi T., Ji B., Ono M., Hattori S., Kumata K., Iwata N., Saido T.C., Trojanowski J.Q., Lee V.M., Staufenbiel M., Tomiyama T., Mori H., Fukumura T., Suhara T., Higuchi M. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J. Neurosci. 2011, 31(12):4720-4730. ([Internet], Mar 23).
160. 11C]PiB and its multi-modal validation in an APP/PS1 mouse model of Alzheimer's disease. PLoS One 2012, 7(3):e31310. (Internet).
161. Marcello A., Wirths O., Schneider-Axmann T., Degerman-Gunnarsson M., Lannfelt L., Bayer T.A. Reduced levels of IgM autoantibodies against N-truncated pyroglutamate abeta in plasma of patients with Alzheimer's disease. Neurobiol. Aging 2011, 32(8):1379-1387. ([Internet], Aug).
162. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(33):11906-11910. ([Internet], Aug 16).
163. Mattsson N., Rosen E., Hansson O., Andreasen N., Parnetti L., Jonsson M., Herukka S.K., van der Flier W.M., Blankenstein M.A., Ewers M., Rich K., Kaiser E., Verbeek M.M., Olde Rikkert M., Tsolaki M., Mulugeta E., Aarsland D., Visser P.J., Schroder J., Marcusson J., de Leon M., Hampel H., Scheltens P., Wallin A., Eriksdotter-Jonhagen M., Minthon L., Winblad B., Blennow K., Zetterberg H. Age and diagnostic performance of alzheimer disease CSF biomarkers. Neurology 2012, 78(7):468-476. ([Internet], Feb 14).
164. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330(6012):1774. ([Internet], Dec 24).
165. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003, 61(9):1185-1190. ([Internet], Nov 11).
166. Mazere J., Prunier C., Barret O., Guyot M., Hommet C., Guilloteau D., Dartigues J.F., Auriacombe S., Fabrigoule C., Allard M. In vivo SPECT imaging of vesicular acetylcholine transporter using [(123)I]-IBVM in early Alzheimer's disease. Neuroimage 2008, 40(1):280-288. ([Internet], Mar 1).
167. Medina D., DeToledo-Morrell L., Urresta F., Gabrieli J.D., Moseley M., Fleischman D., Bennett D.A., Leurgans S., Turner D.A., Stebbins G.T. White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol. Aging 2006, 27(5):663-672. ([Internet], May).
168. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in alzheimer disease. Arch. Neurol. 2000, 57(1):100-105. ([Internet], Jan).
169. Moffett J.R., Ross B., Arun P., Madhavarao C.N., Namboodiri A.M. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog. Neurobiol. 2007, 81(2):89-131. ([Internet], Feb).
170. Moghekar A., Goh J., Li M., Albert M., O'Brien R.J. Cerebrospinal fluid abeta and tau level fluctuation in an older clinical cohort. Arch. Neurol. 2012, 69(2):246-250. ([Internet], Feb).
171. Montine T.J., Beal M.F., Cudkowicz M.E., O'Donnell H., Margolin R.A., McFarland L., Bachrach A.F., Zackert W.E., Roberts L.J., Morrow J.D. Increased CSF F2-isoprostane concentration in probable AD. Neurology 1999, 52(3):562-565. ([Internet], Feb).
172. Montine T.J., Shinobu L., Montine K.S., Roberts L.J., Kowall N.W., Beal M.F., Morrow J.D. No difference in plasma or urinary F2-isoprostanes among patients with Huntington's disease or Alzheimer's disease and controls. Ann. Neurol. 2000, 48(6):950. ([Internet], Dec).
173. Montine T.J., Kaye J.A., Montine K.S., McFarland L., Morrow J.D., Quinn J.F. Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. Arch. Pathol. Lab. Med. 2001, 125(4):510-512. ([Internet], Apr).
174. Montine T.J., Peskind E.R., Quinn J.F., Wilson A.M., Montine K.S., Galasko D. Increased cerebrospinal fluid F2-isoprostanes are associated with aging and latent Alzheimer's disease as identified by biomarkers. Neuromolecular Med. 2011, 13(1):37-43. ([Internet], Mar).
175. Mosconi L., Perani D., Sorbi S., Herholz K., Nacmias B., Holthoff V., Salmon E., Baron J.C., De Cristofaro M.T., Padovani A., Borroni B., Franceschi M., Bracco L., Pupi A. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004, 63(12):2332-2340. ([Internet], Dec 28).
176. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci. 2002, 22(16):7218-7224. ([Internet], Aug 15).
177. Mueggler T., Baumann D., Rausch M., Staufenbiel M., Rudin M. Age-dependent impairment of somatosensory response in the amyloid precursor protein 23 transgenic mouse model of Alzheimer's disease. J. Neurosci. 2003, 23(23):8231-8236. ([Internet], Sep 10).
178. Nestor P.J., Caine D., Fryer T.D., Clarke J., Hodges J.R. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J. Neurol. Neurosurg. Psychiatry 2003, 74(11):1521-1529. ([Internet], Nov).
179. Nicholson R.M., Kusne Y., Nowak L.A., LaFerla F.M., Reiman E.M., Valla J. Regional cerebral glucose uptake in the 3xTG model of Alzheimer's disease highlights common regional vulnerability across AD mouse models. Brain Res. 2010, 1347:179-185. ([Internet], Aug 6).
180. 18F]FDDNP. Synapse 2008, 62(6):472-475. ([Internet], Jun).
181. Oberg J., Spenger C., Wang F.H., Andersson A., Westman E., Skoglund P., Sunnemark D., Norinder U., Klason T., Wahlund L.O., Lindberg M. Age related changes in brain metabolites observed by 1H MRS in APP/PS1 mice. Neurobiol. Aging 2008, 29(9):1423-1433. ([Internet], Sep).
182. O'Brien J.T., Colloby S., Fenwick J., Williams E.D., Firbank M., Burn D., Aarsland D., McKeith I.G. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch. Neurol. 2004, 61(6):919-925. ([Internet], Jun).
183. 123I-5IA-85380 single-photon-emission computed tomography. J. Neurol. Neurosurg. Psychiatry 2007, 78(4):356-362. ([Internet], Apr).
184. Okello A., Edison P., Archer H.A., Turkheimer F.E., Kennedy J., Bullock R., Walker Z., Kennedy A., Fox N., Rossor M., Brooks D.J. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72(1):56-62. ([Internet], Jan 6).
185. 123I-QNB SPECT. J. Neurol. 2007, 254(7):907-913. ([Internet], Jul).
186. Pike K.E., Savage G., Villemagne V.L., Ng S., Moss S.A., Maruff P., Mathis C.A., Klunk W.E., Masters C.L., Rowe C.C. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt 11):2837-2844. ([Internet], Nov).
187. Platt B., Drever B., Koss D., Stoppelkamp S., Jyoti A., Plano A., Utan A., Merrick G., Ryan D., Melis V., Wan H., Mingarelli M., Porcu E., Scrocchi L., Welch A., Riedel G. Abnormal cognition, sleep, EEG and brain metabolism in a novel knock-in Alzheimer mouse, PLB1. PLoS One 2011, 6(11):e27068. (Internet).
188. Poduslo J.F., Wengenack T.M., Curran G.L., Wisniewski T., Sigurdsson E.M., Macura S.I., Borowski B.J., Jack C.R. Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol. Dis. 2002, 11(2):315-329. ([Internet], Nov).
189. Poduslo J.F., Hultman K.L., Curran G.L., Preboske G.M., Chamberlain R., Marjanska M., Garwood M., Jack C.R., Wengenack T.M. Targeting vascular amyloid in arterioles of alzheimer disease transgenic mice with amyloid beta protein antibody-coated nanoparticles. J. Neuropathol. Exp. Neurol. 2011, 70(8):653-661. ([Internet], Aug).
190. 18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition. Neurobiol. Aging 2012, 33(11):256-271.
191. Pratico D. The neurobiology of isoprostanes and Alzheimer's disease. Biochim. Biophys. Acta 2010, 1801(8):930-933. ([Internet], Aug).
192. Pratico D., MY Lee V., Trojanowski J.Q., Rokach J., Fitzgerald G.A. Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998, 12(15):1777-1783. ([Internet], Dec).
193. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 2000, 48(5):809-812. ([Internet], Nov).
194. Pratico D., Uryu K., Leight S., Trojanoswki J.Q., Lee V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J. Neurosci. 2001, 21(12):4183-4187. ([Internet], Jun 15).
195. Puchades M., Hansson S.F., Nilsson C.L., Andreasen N., Blennow K., Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res. Mol. Brain Res. 2003, 118(1-2):140-146. ([Internet], Oct 21).
196. Quinn J.F., Montine K.S., Moore M., Morrow J.D., Kaye J.A., Montine T.J. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J. Alzheimers Dis. 2004, 6(1):93-97. ([Internet], Feb).
197. Ramesh B.N., Raichurkar K.P., Shamasundar N.M., Rao T.S., Rao K.S. Abeta(42) induced MRI changes in aged rabbit brain resembles AD brain. Neurochem. Int. 2011, 59(5):637-642. ([Internet], Oct).
198. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 2007, 13(11):1359-1362. ([Internet], Nov).
199. Redwine J.M., Kosofsky B., Jacobs R.E., Games D., Reilly J.F., Morrison J.H., Young W.G., Bloom F.E. Dentate gyrus volume is reduced before onset of plaque formation in PDAPP mice: a magnetic resonance microscopy and stereologic analysis. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(3):1381-1386. ([Internet], Feb 4).
200. Reiman E.M., Uecker A., Gonzalez-Lima F., Minear D., Chen K., Callaway N.L., Berndt J.D., Games D. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000, 11(5):987-991. ([Internet], Apr 7).
201. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch. Neurol. 2002, 59(11):1729-1734. ([Internet], Nov).
202. Ringman J.M., O'Neill J., Geschwind D., Medina L., Apostolova L.G., Rodriguez Y., Schaffer B., Varpetian A., Tseng B., Ortiz F., Fitten J., Cummings J.L., Bartzokis G. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007, 130(Pt 7):1767-1776. ([Internet], Jul).
203. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., Rodriguez-Agudelo Y., Schaffer B., Fein J., Sokolow S., Rosario E.R., Gylys K.H., Varpetian A., Medina L.D., Cummings J.L. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008, 71(2):85-92. ([Internet], Jul 8).
204. Rodrigue K.M., Kennedy K.M., Devous M.D.S., Rieck J.R., Hebrank A.C., Diaz-Arrastia R., Mathews D., Park D.C. Beta-amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 2012, 78(6):387-395. ([Internet], Feb 7).
205. Rombouts S.A., Barkhof F., Van Meel C.S., Scheltens P. Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2002, 73(6):665-671. ([Internet], Dec).
206. Rombouts S.A., Barkhof F., Goekoop R., Stam C.J., Scheltens P. Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum. Brain Mapp. 2005, 26(4):231-239. ([Internet], Dec).
207. Rose S.E., Chen F., Chalk J.B., Zelaya F.O., Strugnell W.E., Benson M., Semple J., Doddrell D.M. Loss of connectivity in Alzheimer's disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J. Neurol. Neurosurg. Psychiatry 2000, 69(4):528-530. ([Internet], Oct).
208. Rossini P.M., Buscema M., Capriotti M., Grossi E., Rodriguez G., Del Percio C., Babiloni C. Is it possible to automatically distinguish resting EEG data of normal elderly vs. mild cognitive impairment subjects with high degree of accuracy?. Clin. Neurophysiol. 2008, 119(7):1534-1545. ([Internet], Jul).
209. Rota E., Bellone G., Rocca P., Bergamasco B., Emanuelli G., Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 2006, 27(1):33-39. ([Internet], Apr).
210. Rowe C.C., Ng S., Ackermann U., Gong S.J., Pike K., Savage G., Cowie T.F., Dickinson K.L., Maruff P., Darby D., Smith C., Woodward M., Merory J., Tochon-Danguy H., O'Keefe G., Klunk W.E., Mathis C.A., Price J.C., Masters C.L., Villemagne V.L. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68(20):1718-1725. ([Internet], May 15).
211. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008, 7(2):129-135. ([Internet], Feb).
212. Sabbagh J.J., Kinney J.W., Cummings J.L. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging 2013, 34(1):169-183. ([Internet], Jan).
213. Sanchez-Ramos J., Song S., Sava V., Catlow B., Lin X., Mori T., Cao C., Arendash G.W. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience 2009, 163(1):55-72. ([Internet], Sep 29).
214. Sankaranarayanan S., Holahan M.A., Colussi D., Crouthamel M.C., Devanarayan V., Ellis J., Espeseth A., Gates A.T., Graham S.L., Gregro A.R., Hazuda D., Hochman J.H., Holloway K., Jin L., Kahana J., Lai M.T., Lineberger J., McGaughey G., Moore K.P., Nantermet P., Pietrak B., Price E.A., Rajapakse H., Stauffer S., Steinbeiser M.A., Seabrook G., Selnick H.G., Shi X.P., Stanton M.G., Swestock J., Tugusheva K., Tyler K.X., Vacca J.P., Wong J., Wu G., Xu M., Cook J.J., Simon A.J. First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates. J. Pharmacol. Exp. Ther. 2009, 328(1):131-140. ([Internet], Jan).
215. Santos A.N., Ewers M., Minthon L., Simm A., Silber R.E., Blennow K., Prvulovic D., Hansson O., Hampel H. Amyloid-beta oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J. Alzheimers Dis. 2012, 29(1):171-176. ([Internet], Jan 1).
216. Schuff N., Amend D., Ezekiel F., Steinman S.K., Tanabe J., Norman D., Jagust W., Kramer J.H., Mastrianni J.A., Fein G., Weiner M.W. Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 1997, 49(6):1513-1521. ([Internet], Dec).
217. Schupf N., Tang M.X., Fukuyama H., Manly J., Andrews H., Mehta P., Ravetch J., Mayeux R. Peripheral abeta subspecies as risk biomarkers of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(37):14052-14057. ([Internet], Sep 16).
218. Sehlin D., Sollvander S., Paulie S., Brundin R., Ingelsson M., Lannfelt L., Pettersson F.E., Englund H. Interference from heterophilic antibodies in amyloid-beta oligomer ELISAs. J. Alzheimers Dis. 2010, 21(4):1295-1301. (Internet).
219. Shanks M.F., McGeown W.J., Forbes-McKay K.E., Waiter G.D., Ries M., Venneri A. Regional brain activity after prolonged cholinergic enhancement in early Alzheimer's disease. Magn. Reson. Imaging 2007, 25(6):848-859. ([Internet], Jul).
220. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q., Alzheimer's Disease Neuroimaging Initiative Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65(4):403-413. ([Internet], Apr).
221. Shi J., Perry G., Berridge M.S., Aliev G., Siedlak S.L., Smith M.A., LaManna J.C., Friedland R.P. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J. Nucl. Med. 2002, 43(8):1044-1051. ([Internet], Aug).
222. Shin J., Lee S.Y., Kim S.H., Kim Y.B., Cho S.J. Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease. Neuroimage 2008, 43(2):236-244. ([Internet], Nov 1).
223. Shin J., Kepe V., Barrio J.R., Small G.W. The merits of FDDNP-PET imaging in Alzheimer's disease. J. Alzheimers Dis. 2011, 26(Suppl. 3):135-145. (Internet).
224. Shoghi-Jadid K., Small G.W., Agdeppa E.D., Kepe V., Ercoli L.M., Siddarth P., Read S., Satyamurthy N., Petric A., Huang S.C., Barrio J.R. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am. J. Geriatr. Psychiatry 2002, 10(1):24-35. ([Internet], Jan-Feb).
225. Shoji M., Matsubara E., Murakami T., Manabe Y., Abe K., Kanai M., Ikeda M., Tomidokoro Y., Shizuka M., Watanabe M., Amari M., Ishiguro K., Kawarabayashi T., Harigaya Y., Okamoto K., Nishimura T., Nakamura Y., Takeda M., Urakami K., Adachi Y., Nakashima K., Arai H., Sasaki H., Kanemaru K., Yamanouchi H., Yoshida Y., Ichise K., Tanaka K., Hamamoto M., Yamamoto H., Matsubayashi T., Yoshida H., Toji H., Nakamura S., Hirai S. Cerebrospinal fluid tau in dementia disorders: a large scale multicenter study by a Japanese study group. Neurobiol. Aging 2002, 23(3):363-370. ([Internet], May-Jun).
226. Shonk T.K., Moats R.A., Gifford P., Michaelis T., Mandigo J.C., Izumi J., Ross B.D. Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 1995, 195(1):65-72. ([Internet], Apr).
227. Sigurdsson E.M., Wadghiri Y.Z., Mosconi L., Blind J.A., Knudsen E., Asuni A., Scholtzova H., Tsui W.H., Li Y., Sadowski M., Turnbull D.H., de Leon M.J., Wisniewski T. A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 2008, 29(6):836-847. ([Internet], Jun).
228. Simonsen A.H., McGuire J., Podust V.N., Hagnelius N.O., Nilsson T.K., Kapaki E., Vassilopoulos D., Waldemar G. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement. Geriatr. Cogn. Disord. 2007, 24(6):434-440. (Internet).
229. Simonsen A.H., McGuire J., Podust V.N., Davies H., Minthon L., Skoog I., Andreasen N., Wallin A., Waldemar G., Blennow K. Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol. Aging 2008, 29(7):961-968. ([Internet], Jul).
230. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355(25):2652-2663. ([Internet], Dec 21).
231. Smith K.D., Kallhoff V., Zheng H., Pautler R.G. In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 2007, 35(4):1401-1408. ([Internet], May 1).
232. Song S.K., Kim J.H., Lin S.J., Brendza R.P., Holtzman D.M. Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition. Neurobiol. Dis. 2004, 15(3):640-647. ([Internet], Apr).
233. Sorg C., Riedl V., Muhlau M., Calhoun V.D., Eichele T., Laer L., Drzezga A., Forstl H., Kurz A., Zimmer C., Wohlschlager A.M. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(47):18760-18765. ([Internet], Nov 20).
234. Sperling R. Potential of functional MRI as a biomarker in early Alzheimer's disease. Neurobiol. Aging 2011, 32(Suppl. 1):S37-S43. ([Internet], Dec).
235. Sperling R.A., Bates J.F., Chua E.F., Cocchiarella A.J., Rentz D.M., Rosen B.R., Schacter D.L., Albert M.S. fMRI studies of associative encoding in young and elderly controls and mild Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74(1):44-50. ([Internet], Jan).
236. Stam C.J., Montez T., Jones B.F., Rombouts S.A., van der Made Y., Pijnenburg Y.A., Scheltens P. Disturbed fluctuations of resting state EEG synchronization in Alzheimer's disease. Clin. Neurophysiol. 2005, 116(3):708-715. ([Internet], Mar).
237. Stebbins G.T., Murphy C.M. Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behav. Neurol. 2009, 21(1):39-49. (Internet).
238. Sun S.W., Song S.K., Harms M.P., Lin S.J., Holtzman D.M., Merchant K.M., Kotyk J.J. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp. Neurol. 2005, 191(1):77-85. ([Internet], Jan).
239. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003, 289(16):2094-2103. ([Internet], Apr 23-30).
240. Sykova E., Vorisek I., Antonova T., Mazel T., Meyer-Luehmann M., Jucker M., Hajek M., Ort M., Bures J. Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102(2):479-484. ([Internet], Jan 11).
241. Tagawa K., Kunishita T., Maruyama K., Yoshikawa K., Kominami E., Tsuchiya T., Suzuki K., Tabira T., Sugita H., Ishiura S. Alzheimer's disease amyloid beta-clipping enzyme (APP secretase): identification, purification, and characterization of the enzyme. Biochem. Biophys. Res. Commun. 1991, 177(1):377-387. ([Internet], May 31).
242. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., Shoji S. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 1996, 141(1-2):65-68. ([Internet], Sep 15).
243. Tapiola T., Pennanen C., Tapiola M., Tervo S., Kivipelto M., Hanninen T., Pihlajamaki M., Laakso M.P., Hallikainen M., Hamalainen A., Vanhanen M., Helkala E.L., Vanninen R., Nissinen A., Rossi R., Frisoni G.B., Soininen H. MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study. Neurobiol. Aging 2008, 29(1):31-38. ([Internet], Jan).
244. Tarkowski E., Andreasen N., Tarkowski A., Blennow K. Intrathecal inflammation precedes development of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 2003, 74(9):1200-1205. ([Internet], Sep).
245. Teng E., Kepe V., Frautschy S.A., Liu J., Satyamurthy N., Yang F., Chen P.P., Cole G.B., Jones M.R., Huang S.C., Flood D.G., Trusko S.P., Small G.W., Cole G.M., Barrio J.R. [F-18]FDDNP microPET imaging correlates with brain abeta burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-abeta antibody treatment. Neurobiol. Dis. 2011, 43(3):565-575. ([Internet], Sep).
246. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., Simmons A., Murphy D., Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 2008, 255(11):1712-1720. ([Internet], Nov).
247. Tokita Y., Kaji K., Lu J., Okura Y., Kohyama K., Matsumoto Y. Assessment of non-viral amyloid-beta DNA vaccines on amyloid-beta reduction and safety in rhesus monkeys. J. Alzheimers Dis. 2010, 22(4):1351-1361. (Internet).
248. 11C-(R)-PK11195 in patients with Alzheimer's disease. J. Nucl. Med. 2008, 49(8):1249-1256. ([Internet], Aug).
249. Town T., Vendrame M., Patel A., Poetter D., DelleDonne A., Mori T., Smeed R., Crawford F., Klein T., Tan J., Mullan M. Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J. Neuroimmunol. 2002, 132(1-2):49-59. ([Internet], Nov).
250. 11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 2005, 32(5):593-600. ([Internet], May).
251. Valla J., Chen K., Berndt J.D., Gonzalez-Lima F., Cherry S.R., Games D., Reiman E.M. Effects of image resolution on autoradiographic measurements of posterior cingulate activity in PDAPP mice: implications for functional brain imaging studies of transgenic mouse models of Alzheimer's disease. Neuroimage 2002, 16(1):1-6. ([Internet], May).
252. Valla J., Schneider L.E., Gonzalez-Lima F., Reiman E.M. Nonprogressive transgene-related callosal and hippocampal changes in PDAPP mice. Neuroreport 2006, 17(8):829-832. ([Internet], May 29).
253. Van Broeck B., Vanhoutte G., Pirici D., Van Dam D., Wils H., Cuijt I., Vennekens K., Zabielski M., Michalik A., Theuns J., De Deyn P.P., Van der Linden A., Van Broeckhoven C., Kumar-Singh S. Intraneuronal amyloid beta and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease. Neurobiol. Aging 2008, 29(2):241-252. ([Internet], Feb).
254. van Deursen J.A., Vuurman E.F., Verhey F.R., van Kranen-Mastenbroek V.H., Riedel W.J. Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impairment. J. Neural Transm. 2008, 115(9):1301-1311. ([Internet], Sep).
255. Vanhoutte G., Dewachter I., Borghgraef P., Van Leuven F., Van der Linden A. Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magn. Reson. Med. 2005, 53(3):607-613. ([Internet], Mar).
256. Vemuri P., Wiste H.J., Weigand S.D., Knopman D.S., Trojanowski J.Q., Shaw L.M., Bernstein M.A., Aisen P.S., Weiner M., Petersen R.C., Jack C.R., Alzheimer's Disease Neuroimaging Initiative Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 2010, 75(2):143-151. ([Internet], Jul 13).
257. Venneri A., McGeown W.J., Shanks M.F. Responders to ChEI treatment of Alzheimer's disease show restitution of normal regional cortical activation. Curr. Alzheimer Res. 2009, 6(2):97-111. ([Internet], Apr).
258. Venneti S., Lopresti B.J., Wang G., Hamilton R.L., Mathis C.A., Klunk W.E., Apte U.M., Wiley C.A. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol. Aging 2009, 30(8):1217-1226. ([Internet], Aug).
259. 18F-florbetaben in alzheimer disease and other dementias. J. Nucl. Med. 2011, 52(8):1210-1217. ([Internet], Aug).
260. Wadghiri Y.Z., Sigurdsson E.M., Sadowski M., Elliott J.I., Li Y., Scholtzova H., Tang C.Y., Aguinaldo G., Pappolla M., Duff K., Wisniewski T., Turnbull D.H. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Med. 2003, 50(2):293-302. ([Internet], Aug).
261. Walker Z., Costa D.C., Walker R.W., Shaw K., Gacinovic S., Stevens T., Livingston G., Ince P., McKeith I.G., Katona C.L. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J. Neurol. Neurosurg. Psychiatry 2002, 73(2):134-140. ([Internet], Aug).
262. Walsh D.M., Klyubin I., Fadeeva J.V., Cullen W.K., Anwyl R., Wolfe M.S., Rowan M.J., Selkoe D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002, 416(6880):535-539. ([Internet], Apr 4).
263. Wang J., Ikonen S., Gurevicius K., van Groen T., Tanila H. Alteration of cortical EEG in mice carrying mutated human APP transgene. Brain Res. 2002, 943(2):181-190. ([Internet], Jul 12).
264. Wang L., Zang Y., He Y., Liang M., Zhang X., Tian L., Wu T., Jiang T., Li K. Changes in hippocampal connectivity in the early stages of Alzheimer's disease: evidence from resting state fMRI. Neuroimage 2006, 31(2):496-504. ([Internet], Jun).
265. Weidensteiner C., Metzger F., Bruns A., Bohrmann B., Kuennecke B., von Kienlin M. Cortical hypoperfusion in the B6.PS2APP mouse model for Alzheimer's disease: comprehensive phenotyping of vascular and tissular parameters by MRI. Magn. Reson. Med. 2009, 62(1):35-45. ([Internet], Jul).
266. Weiss C., Venkatasubramanian P.N., Aguado A.S., Power J.M., Tom B.C., Li L., Chen K.S., Disterhoft J.F., Wyrwicz A.M. Impaired eyeblink conditioning and decreased hippocampal volume in PDAPP V717F mice. Neurobiol. Dis. 2002, 11(3):425-433. ([Internet], Dec).
267. Wengenack T.M., Jack C.R., Garwood M., Poduslo J.F. MR microimaging of amyloid plaques in Alzheimer's disease transgenic mice. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(Suppl. 1):S82-S88. ([Internet], Mar).
268. Wierenga C.E., Stricker N.H., McCauley A., Simmons A., Jak A.J., Chang Y.L., Nation D.A., Bangen K.J., Salmon D.P., Bondi M.W. Altered brain response for semantic knowledge in Alzheimer's disease. Neuropsychologia 2011, 49(3):392-404. ([Internet], Feb).
269. Wirths O., Erck C., Martens H., Harmeier A., Geumann C., Jawhar S., Kumar S., Multhaup G., Walter J., Ingelsson M., Degerman-Gunnarsson M., Kalimo H., Huitinga I., Lannfelt L., Bayer T.A. Identification of low molecular weight pyroglutamate A{beta} oligomers in alzheimer disease: a novel tool for therapy and diagnosis. J. Biol. Chem. 2010, 285(53):41517-41524. ([Internet], Dec 31).
270. 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 2010, 51(6):913-920. ([Internet], Jun).
271. 1H HR-MAS. Behav. Brain Res. 2010, 211(1):125-131. ([Internet], Jul 29).
272. Xu W., Zhan Y., Huang W., Wang X., Zhang S., Lei H. Reduction of hippocampal N-acetyl aspartate level in aged APP(swe)/PS1(dE9) transgenic mice is associated with degeneration of CA3 pyramidal neurons. J. Neurosci. Res. 2010, 88(14):3155-3160. ([Internet], Nov 1).
273. 19F-containing curcumin derivative in a mouse model of Alzheimer's disease. Neuroscience 2011, 184:120-127. ([Internet], Jun 16).
274. Yang D., Xie Z., Stephenson D., Morton D., Hicks C.D., Brown T.M., Sriram R., O'Neill S., Raunig D., Bocan T. Volumetric MRI and MRS provide sensitive measures of Alzheimer's disease neuropathology in inducible tau transgenic mice (rTg4510). Neuroimage 2011, 54(4):2652-2658. ([Internet], Feb 14).
275. Yang J., Wadghiri Y.Z., Hoang D.M., Tsui W., Sun Y., Chung E., Li Y., Wang A., de Leon M., Wisniewski T. Detection of amyloid plaques targeted by USPIO-Abeta1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 2011, 55(4):1600-1609. ([Internet], Apr 15).
276. Zetterberg H., Pedersen M., Lind K., Svensson M., Rolstad S., Eckerstrom C., Syversen S., Mattsson U.B., Ysander C., Mattsson N., Nordlund A., Vanderstichele H., Vanmechelen E., Jonsson M., Edman A., Blennow K., Wallin A. Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J. Alzheimers Dis. 2007, 12(3):255-260. ([Internet], Nov).
277. Zetterberg H., Andreasson U., Hansson O., Wu G., Sankaranarayanan S., Andersson M.E., Buchhave P., Londos E., Umek R.M., Minthon L., Simon A.J., Blennow K. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 2008, 65(8):1102-1107. ([Internet], Aug).
278. Zhang J., Goodlett D.R., Quinn J.F., Peskind E., Kaye J.A., Zhou Y., Pan C., Yi E., Eng J., Wang Q., Aebersold R.H., Montine T.J. Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J. Alzheimers Dis. 2005, 7(2):125-133. ([Internet], Apr, discussion 173-80).
279. Zhang Y., Schuff N., Jahng G.H., Bayne W., Mori S., Schad L., Mueller S., Du A.T., Kramer J.H., Yaffe K., Chui H., Jagust W.J., Miller B.L., Weiner M.W. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007, 68(1):13-19. ([Internet], Jan 2).
280. Zhong Z., Ewers M., Teipel S., Burger K., Wallin A., Blennow K., He P., McAllister C., Hampel H., Shen Y. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 2007, 64(6):718-726. ([Internet], Jun).
281. Zilka N., Korenova M., Kovacech B., Iqbal K., Novak M. CSF phospho-tau correlates with behavioural decline and brain insoluble phospho-tau levels in a rat model of tauopathy. Acta Neuropathol. 2010, 119(6):679-687. ([Internet], Jun).